503 — Lansen Pharmaceutical Holdings Share Price
Last trade - 00:00- HK$750.60m
- HK$527.08m
- $65.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.78 | ||
| Price to Tang. Book | 1 | ||
| Price to Free Cashflow | 112.97 | ||
| Price to Sales | 1.48 | ||
| EV to EBITDA | 4.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.03% | ||
| Return on Equity | 5.97% | ||
| Operating Margin | 17.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 56.87 | 54.26 | 54.39 | 54.18 | 65.56 | n/a | n/a | -6.03% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +1982.08 | -92.61 | +184.03 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lansen Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company operates through three segments. Specialty Pharmaceuticals segment is engaged in the development, production and sales of specialty pharmaceuticals mainly used in the fields of rheumatology and dermatology. Its main specialty pharmaceutical products include pafulin, leflunomide tablets and mycophenolate mofetil dispersible tablets. Plant Extract and Healthcare Products segment is engaged in the development, production and sales of Chinese medicine extracts and healthcare products. Other Pharmaceuticals segment is engaged in businesses related to other pharmaceuticals.
Directors
- Zhen Tao Wu NEC (63)
- Li Chen CEO (56)
- Rong Zhou SVP (45)
- Xiao Yun Chen VPR (46)
- Guang Xu GMG (40)
- Hua Zhong Cheng OTH (42)
- Wei Jun Li OTH (36)
- Di Han Zhu OTH (40)
- Kai Fai Pang SEC
- Stephen Hunt NED (75)
- Xuezi Liu NED (39)
- Ching Har Chan NID (64)
- Kee Huen Chan NID (67)
- Tak Bun Yeung NID (52)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 10th, 2009
- Public Since
- May 7th, 2010
- No. of Employees
- 652
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 419,328,434
- Address
- Room 109, Building 14, NINGBO, 315174
- Web
- http://www.lansen.com.cn/
- Phone
- +86 57488046316
- Contact
- Kai Fai Pang
- Auditors
- BDO LTD
Upcoming Events for 503
Similar to 503
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 18:13 UTC, shares in Lansen Pharmaceutical Holdings are trading at HK$1.79. This share price information is delayed by 15 minutes.
Shares in Lansen Pharmaceutical Holdings last closed at HK$1.79 and the price had moved by +20.95% over the past 365 days. In terms of relative price strength the Lansen Pharmaceutical Holdings share price has outperformed the FTSE Developed Asia Pacific Index by +19.72% over the past year.
There is no consensus recommendation for this security.
Lansen Pharmaceutical Holdings does not currently pay a dividend.
Lansen Pharmaceutical Holdings does not currently pay a dividend.
Lansen Pharmaceutical Holdings does not currently pay a dividend.
To buy shares in Lansen Pharmaceutical Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$1.79, shares in Lansen Pharmaceutical Holdings had a market capitalisation of HK$750.60m.
Here are the trading details for Lansen Pharmaceutical Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 503
Based on an overall assessment of its quality, value and momentum Lansen Pharmaceutical Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lansen Pharmaceutical Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +43.74%.
As of the last closing price of HK$1.79, shares in Lansen Pharmaceutical Holdings were trading +17.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lansen Pharmaceutical Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$1.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lansen Pharmaceutical Holdings' management team is headed by:
- Zhen Tao Wu - NEC
- Li Chen - CEO
- Rong Zhou - SVP
- Xiao Yun Chen - VPR
- Guang Xu - GMG
- Hua Zhong Cheng - OTH
- Wei Jun Li - OTH
- Di Han Zhu - OTH
- Kai Fai Pang - SEC
- Stephen Hunt - NED
- Xuezi Liu - NED
- Ching Har Chan - NID
- Kee Huen Chan - NID
- Tak Bun Yeung - NID